I think they have laid out a pretty clear plan.
As to the Immunotronics platform..
Our goal remains simple - complete our pre-clinical trials, release positive data, and aggressively continue down the regulatory pathway.
Many on the board were questioning whether the other pre clinical trials had commenced despite the company stating that they had. Now with the release of the critical limb ischemia results, this is confirmed. There is no reason to believe that the kidney and liver studies are not soon to be released as well.
As to the financing...
While our goal to uplist has not waivered, the Company believes it remains in our best interest to pursue so after we receive positive results from our studies coupled with a binding funding commitment, minimizing dilution.
"Now having completed this acquisition, we are looking to position the company for continued growth by redeeming our outstanding convertible notes and uplisting the company onto a national stock exchange where we can increase shareholder value."
Endonovo has announced a Senior Secured Series C Preferred Stock Offering (the "Series C Stock") to raise up to $8 million in funding."
Numerous times the company has stated that they intend to release their pre clinical data before seeking new funding. We still have 2 sets of results to be released as well as follow up on previously released data. The intent of the series c preferred shares has not been fully disclosed, we know a portion was used for the acquisition of RGN. As they continue to bring in new investors, now well over a million dollars as last reported, we have the possibility of this capitol being used to redeem the note from Eagle as well.
As to the tpemf platform...
Endonovo plans to complete a single center, prospective, controlled, clinical trial of tPEMF to evaluate the effects of tPEMF in patients with brain injury and external ventricular drain (EVD) in an intensive care unit (ICU) setting. This clinical study is an extension of a safety trial and will be open to all patients who have or are fitted with an external ventricular drain (EVD) to remove excess cerebrospinal fluid (CSF).
Endonovo plans to redesign tPEMF products for use in CNS disorders in order to make its tPEMF therapy easier to use and increase patient compliance. Endonovo believes that industrial design and engineering of non-invasive electroceutical devices will be a critical component to the precise stimulation of areas in the CNS that require treatment and allow patients to use the therapy in an in-home setting.
Endonovo plans to initiate previously planned clinical trials to study the effects of tPEMF in patients with Post-Concussion Syndrome (PCS) and Acute Sports-related Concussions upon the redesign of its tPEMF devices for use in CNS disorders.
Endonovo plans to initiate an open-label study of tPEMF treatment in patients with multiple sclerosis (MS) that will be used to assess feasibility and tolerability of tPEMF therapy and to generate preliminary data on clinically relevant outcomes.
In addition the company has also stated their intent to have clinical studies on stroke as well.
As to Sofpulse, their FDA approved, CE marked device...
Endonovo plans to commercialize its CE-Marked and FDA-Cleared Electroceutical™ therapy in China, Japan, Korea and other international markets. Endonovo has already initiated dialogue with potential licensees, distributors and joint venture partners in Asia. Endonovo will further look to establish distribution agreements and licenses in the Unites States for cosmetic surgery and orthopedic indications or explore the establishment of its own sales and marketing channels.
Furthermore, the Company announced it is seeking distribution partners in Europe for SofPulse™, which is CE-Marked for the promotion of wound healing, reduction of pain and post-operative edema.
1-2 license agreements to be signed by the end of 2018
From what I have researched the commercialization of Sofpulse was not aggressively pursued by either of its previous owners. The sales generated came from sales in the US and were produced with a very small sales team. With the CEO's prior experience in international licensing we will likely see at the least some licencing deals, hopefully a joint venture, is the course of this year.
As far as the Cytotronics platform...
Though this part of the company has not been mentioned in over a year now, Endonovo has received a full patent on this technology. This platform has the potential for licencing as well. With 80 fold expansion rates, far exceeding current production rates, and cells created in a much more natural process with not only short term propagators but long term as well, this would be an attractive technology to any stem cell provider, cord blood provider, cryogenic provider, as well as toxicology testing company. If we learned anything from the acquisition of RGN, we learned that just because the company is not talking about it does not mean they are not pursuing it.
Seems to me the company has a pretty clear idea of where they are headed. Again if you project the progress they have made in the last three years going forward a lot should be expected here.
News 
Market Data 
Discover 
